CELEX: 62017TA0354
Language: en
Date: 2018-04-23 00:00:00
Title: Case T-354/17: Judgment of the General Court of 23 April 2018 — Genomic Health v EUIPO (ONCOTYPE DX GENOMIC PROSTATE SCORE) (EU trade mark — Application for EU word mark ONCOTYPE DX GENOMIC PROSTATE SCORE — Absolute ground for refusal — Descriptiveness — Article 7(1)(c) of Regulation (EC) No 207/2009 (now Article 7(1)(c) of Regulation (EU) 2017/1001) — Equal treatment)

201805250431897002018/C 200/553542017TC20020180611EN01ENINFO_JUDICIAL20180423424322Case T-354/17: Judgment of the General Court of 23 April 2018 — Genomic Health v EUIPO (ONCOTYPE DX GENOMIC PROSTATE SCORE) (EU trade mark — Application for EU word mark ONCOTYPE DX GENOMIC PROSTATE SCORE — Absolute ground for refusal — Descriptiveness — Article 7(1)(c) of Regulation (EC) No 207/2009 (now Article 7(1)(c) of Regulation (EU) 2017/1001) — Equal treatment)
 ---documentbreak--- C2002018EN4220120180423EN0055422432Judgment of the General Court of 23 April 2018 — Genomic Health v EUIPO (ONCOTYPE DX GENOMIC PROSTATE SCORE)
   (Case T-354/17) (
         1
      )
   ‛(EU trade mark — Application for EU word mark ONCOTYPE DX GENOMIC PROSTATE SCORE — Absolute ground for refusal — Descriptiveness — Article 7(1)(c) of Regulation (EC) No 207/2009 (now Article 7(1)(c) of Regulation (EU) 2017/1001) — Equal treatment)’2018/C 200/55Language of the case: English
      Parties
   
   
      Applicant: Genomic Health, Inc. (Redwood City, California, United States of America) (represented by: A. Reid, Solicitor)
   
      Defendant: European Union Intellectual Property Office (represented by: J. Ivanauskas and K. Sidat Humphreys, acting as Agents)
   
      Re:
   
   Action brought against the decision of the Fifth Board of Appeal of EUIPO of 14 February 2017 (Case R 1682/2016-5), concerning an application for registration of the word sign ONCOTYPE DX GENOMIC PROSTATE SCORE as an EU trade mark.
   
      Operative part of the judgment
   
   The Court:
   
            1.
         
         
            Dismisses the action;
         
      
            2.
         
         
            Orders Genomic Health, Inc., to pay the costs.
         
      (
         1
      )	OJ C 249, 31.7.2017.